A New Model For Funding Research
| Feb 21, 2014 9:00 AM
When Dr. Randall Olson told me about the partnership between the John A. Moran Eye Center, Voyant Biotherapeutics and Allergan, Inc., I was hopeful for the future of research.
This partnership is the true crystallization of the kind of innovative and collaborative thinking that will help us continue to advance the science and delivery of health care for patients worldwide. Our current research environment—constrained by National Institutes of Health funding cuts and by new clinical reimbursement models waiting on the health care horizon—must find support in new and inventive partnership models like this.
We are so proud of the remarkable care and translational science emerging from the teams at Moran, Voyant and its Center for Translational Medicine. Building on their histories of cutting-edge discovery, novel diagnostics and creative new treatments these groups are truly leveraging their strengths to improve care for all and to cement University of Utah Health Science’s place as a center of excellence in ophthalmologic research and delivery.
This partnership would not have been possible without the leadership of Dr. Randall Olson and Gregory Hageman, Ph.D. We are grateful for the talent of their teams and their persistence and hard work. I would also like to recognize the leadership and collaboration of Scott Whitcup and the Allergan, Inc. team. Their commitment to innovation through new models of academic-industrial partnerships is just the kind of dedication that will move health care reform forward.
We are truly all in this together, and I look forward to the discoveries this partnership will bring to us as an institution and to our populations as patients.
Author: Vivian S. Lee, M.D., Ph.D., M.B.A.
About the Author: Dr. Vivian S. Lee is the Senior Vice President for Health Sciences at the University of Utah, Dean of the University of Utah School of Medicine, and CEO of University of Utah Health Care. Read her full bio herecomments powered by Disqus